Gabather: Key shareholders show support - VH Corp
This is a third party research report and does not necessarily reflect our views or values
* A directed share issue adds MSEK 4.2 before costs
* First patient enrolment expected as next trigger
* We keep our fair value of SEK 0.06 per share
Gabather has carried out a directed share issue of approximately MSEK 4.2 with
participation from several investors, improving the company’s cash position.
Together with earlier warrant exercises and improved cost control, this
reduces financial risk and extends the funding runway. Further progress
updates on the phase II clinical trial of GT-002 in Denmark are awaited.
* First patient enrolment expected as next trigger
* We keep our fair value of SEK 0.06 per share
Gabather has carried out a directed share issue of approximately MSEK 4.2 with
participation from several investors, improving the company’s cash position.
Together with earlier warrant exercises and improved cost control, this
reduces financial risk and extends the funding runway. Further progress
updates on the phase II clinical trial of GT-002 in Denmark are awaited.